Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: SWOG S0904

BACKGROUND: Vandetanib is an oral tyrosine kinase inhibitor of VEGFR-2/3, EGFR and RET, which has demonstrated clinical activity as a single agent and in combination with taxanes. We explored the efficacy, safety and toxicity of docetaxel and vandetanib in women with recurrent ovarian cancer (OC). M...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Coleman, Robert L., Moon, James, Sood, Anil K., Hu, Wei, Delmore, James E., Bonebrake, Albert J., Anderson, Garnet L, Chambers, Setsuko K., Markman, Maurie
格式: Artigo
語言:Inglês
出版: 2014
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4098779/
https://ncbi.nlm.nih.gov/pubmed/24709487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2014.03.005
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍